Synendos Therapeutics Expands Series A to CHF 24 million with new investment
Synendos Therapeutics Expands Series A to CHF 24 million with new investment - Ysios Capital joins existing syndicate co-led by Kurma Partners and Sunstone Life Science Ventures - This investment brings total Series A financing to CHF 24 million to complete pre-clinical development and progress lead candidate through proof-of-concept clinical studies - In addition, Synendos Therapeutics secures prestigious Eurostars grant (EU funding scheme) to expand proof-of-concept preclinical studies for PTSD - Professor Jutta Heim appointed as Chair to the Board News provided by Share this article Share ...
Source: prnewswire.com